BA.5 is the. It wasin February 2022 and is closely related to BA.2, the variant currently still dominant in New Ҷֱ.
It carries distinct mutations in the spike protein, two of which are associated with higher transmissibility and immune evasion. The rise in BA.5 seems to stem from its ability to infect people who were immune to earlier variants, but so far there is no indication the variant causes more severe disease.
BA.5 was first detected in the New Ҷֱ community in April and cases have been appearing consistently since May. It has quicklyof sequenced community cases and looks set to become the dominant variant in the next week. It already is dominant in.
ܰshowed a second wave of COVID this year was likely as a consequence of waning immunity, but the spread of BA.5 has hastened its arrival.
What to expect
A big concern at the moment is that case numbers in older age groups are higher now than ever before. The March wave was heavily concentrated in younger people, with under 60s making up 91% of all cases up to the end of April.
That helped keep a lid on the hospitalisation rate and has built strong hybrid immunity, acquired from both infection and vaccination, in these groups. But it leaves a large susceptible population in older groups.
Part of BA.5’s advantage is a better ability to re-infect people who’ve had COVID before. Nevertheless, prior infection with a different variant does provide immunity, however imperfect, and those who haven’t been previously infected are at higher risk of catching the virus in the second wave. In New Ҷֱ, this predominantly means older people.
Waning immunity means many people who are five to six months after their third vaccine dose will have significantly lower immunity now than they did in March.
And winter is flu season. The healthcare system iswith patients with influenza and other winter ailments. Winter weather means people tend to gather indoors, in more crowded and poorly ventilated spaces that create ideal conditions for viruses to spread.
This wave is starting with much busier hospitals than in February, and any additional demand caused by COVID will add more stress to a system already under extreme pressure.
The risk of hospitalisation is aroundin people over 70 compared to younger groups. Even if the number of cases in this wave is lower than in the first wave,the shift in age distribution means it’s possible the number of hospitalisations will actually be higher.
What to do
The vaccine is still our best line of defence against COVID. It provides a high level of protection against getting seriously ill, even if it is less effective at preventing infection with BA.5.
That protection does wane over time, which is why ato over 50s. If you or your whānau are eligible for a vaccination, whether it’s the first dose or the fourth, now is a really good time to get it.
Strong uptake of fourth doses in older age groups, as well as third doses among the, is the best way we have to mitigate this wave.
The influenza vaccine is also important as it can prevent more people getting sick this winter and ease the burden on the healthcare system. Free flu vaccines arefrom GPs and pharmacies for everyone over 65, for Māori and Pacific people over 55, and for children aged between three and 12.
Other easy measures – using high-quality masks indoors, testing and staying home if sick – remain important. Rapid antigen tests (RATs) are an extremely useful tool for managing risk. They are a reliable indicator of whether someone is.
Doing a RAT before visiting a vulnerable person or before large gatherings is an excellent way to reduce risk. They areto anyone with symptoms or whose household members have tested positive.
Even if you test negative on a RAT but have respiratory symptoms, you could have flu or another virus. Staying home when sick is the best way to protect others and reduce the rates of sickness this winter.
The pandemic is clearly not over yet. The virus will continue to evolve to get around our immunity and this will lead to ongoing waves. But we are not helpless in the face of it., better treatments, action to lower transmission through improved ventilation, and the build-up of hybrid immunity will continue to blunt its effects.
This article was originally published on.
